Business Wire

LOOP-ENERGY

6.10.2022 12:31:37 CEST | Business Wire | Press release

Share
Loop Energy Sees Continued Positive Growth in Global Hydrogen Truck Market

Loop Energy™ (TSX: LPEN), a developer and manufacturer of hydrogen fuel cells for commercial mobility, today announces two new customers, each developing medium-duty hydrogen-electric trucks.

Opex, a Colombian systems integrator of batteries and hydrogen fuel cells, and Avia Ingeniería, a Spanish electric powertrain provider and systems integrator, are both looking to trial hydrogen-electric vehicles in 2023.

Loop Energy enters the Pilot Phase of the Customer Adoption Cycle with both companies, expanding its presence in the dynamic European market and establishing its first relationship in the emerging South American market. The news comes after Loop Energy recently upgraded its purchase order guidance for the next 18 months.

Having supplied components and infrastructure for battery-electric vehicles for more than a decade, Opex identified fuel cells as a solution for commercial vehicles in Latin America two years ago. Starting with a prototype, Opex aims to develop a logistics truck using Loop Energy's S300 (30 kW) fuel cell as a range extender. Once built, the truck is expected to be trialed by a local fleet operator to evaluate how the technology can be deployed in larger truck applications.

Avia Ingeniería plans to also apply Loop Energy's 30 kW fuel cell as a range extender in a tractor-trailer transport truck. The truck is a part of the ShineFleet project, which features various Spanish technology and engineering companies including Técnicas Reunidas. The aim of the pilot is to demonstrate the feasibility of hydrogen technology and educate fleet operators on how to scale a fleet. A logistics fleet operator is expected to integrate the truck into its service routes once it is operational in 2023.

"We've seen positive growth when it comes to using fuel cells in medium-duty electric trucks," said Loop Energy Chief Commercial Officer, George Rubin. "Our team continues to identify manufacturers and fleet operators committed to the deployment of hydrogen-electric fleets worldwide. It is great to see Opex and Avia Ingeniería setting a positive example in their respective markets."

Climate Change mitigation, regulatory pressure and energy security concerns are compelling manufacturers and fleet operators to invest in and operate hydrogen-electric trucks instead of traditional diesel combustion engine vehicles. Benefits such as extended range, lighter weight and fast refuelling are key contributors to lower total cost of ownership, making fuel cell-powered vehicles an appealing zero-emissions solution.

About Opex S.A.S.

Opex S.A.S. is a colombian based company with 10 years of experience in the market. Among its main market activities are selling and renting of products as acid lead batteries, Li-Ion batteries, and Hydrogen fuel cells. The company also provides products as forklift trucks and batteries for warehouses, including installations and maintenance of the products. During the last two years, Opex has been involved in several research projects related to clean energies and hydrogen use. We have installed the first hydrogen refueling station in the entire South America region. To learn more visit: www.opex.com.co

About Avia Ingeniería

Avia is an independent company specializing in the design, manufacture of prototypes and small series of special vehicles. The philosophy of the company as engineering is to offer its capacity to develop advanced technology projects and to be present in research projects in the fields of new energies and materials. It offers its clients solutions from the simplest execution of manufacturing drawings to the most advanced integral projects, contributing, with its knowledge, technology and computer resources. Avia brings vast experience in the fields of aeronautics, automotive, agricultural equipment and public works.

About Loop Energy Inc.

Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop's products feature the company's proprietary eFlow™ technology in the fuel cell stack's bipolar plates. eFlow™ is designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.

Forward Looking Warning

This press release contains forward looking information within the meaning of applicable securities legislation, which reflect management’s current expectations and projections regarding future events. Particularly, statements regarding the Company’s or Customer’s expectations of future sales and deployment, performance, achievements, prospects or opportunities or the markets in which we operate is forward looking information, including without limitation statements regarding the trials and deployment of Opex’s and Avia’s hydrogen-electric truck, future purchase orders and projected benefits of fuel cell technology in commercial vehicles.

Forward looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control and could cause actual results and events to vary materially from those that are disclosed, or implied, by such forward looking information. Such risks and uncertainties include, but are not limited to, the ability to scale hydrogen technology into larger applications or fleets, if vehicle OEMs and fleet operators choose not to invest and operate zero-emissions vehicles over diesel vehicles, if the benefits of fuel cell technology in commercials does not contribute to lower total cost of ownership and the factors discussed under “Risk Factors” in the Company’s Annual Information Form dated March 23, 2022. Loop disclaims any obligation to update these forward looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005161/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye